• Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
• Integrated downstream workflows to improve productivity and help speed
  access to critical therapies

Merck, a leading science and technology company,  announced that it has successfully closed the acquisition of the chromatography business of JSR Life Sciences. 

The acquisition adds Amsphere™ Protein A resins and advanced Protein A chromatography capabilities to Merck’s downstream processing portfolio, enabling efficient, scalable purification of monoclonal antibodies. Combined with Merck’s established downstream portfolio, these capabilities help customers improve productivity and support reliable manufacturing from development through commercial scale. 

“This acquisition expands our downstream purification capabilities at a time when customers are pushing to scale biologics faster and more efficiently,” said Sebastián Arana, Head of Process Solutions, Life Science business of Merck. “With expanded Protein A offerings, we can help customers strengthen process consistency, support reliable manufacturing at scale, and ultimately accelerate access to critical therapies.”

With the acquisition, Merck adds a Belgium-based chromatography team of more than 50 employees that supplies chromatography solutions to pharmaceutical and biotech manufacturers worldwide. The team brings strong technical support and application know-how that will further strengthen Merck’s downstream offering for antibody purification. The chromatography business will be integrated into Merck’s Process Solutions portfolio, which supports customers across biopharmaceutical manufacturing from process development to full-scale manufacturing.